You guys seem to want nothing to do with anything that may be seen as adverse and attack it. This information is primarily taken from the companies own 10K. These issues raise real questions that need to be asked in regards to doing due diligence that goes beyond overly brash comments made by an over the top stock promoter that need's to sell subscriptions.
Why no partnerships with big pharma?
Why even have a patent if it's inferior technology that they know they can't use.
Big pharma not in something that is supposed to be so revolutionary doesn't add up truth be told.
Intellectual Property
In their latest 10-K the Company lists an issued patent and two pending patent applications as their intellectual property portfolio. Nanoviricides states that the issued patent is of an inferior technology and that the company will not utilize it. This leaves the two remaining patent applications as the intellectual property that will protect the “nanoviricide” product offering. The Company goes on to state that all of the drugs in their pipeline by themselves may be eligible for patent protection and that the Company plans on filing patent applications for protecting these drugs when they have definitive results from in-vitro or in-vivo studies.
Nanoviricides has no revenues, a questionable IP portfolio, and no partnerships with any major pharmaceutical companies. Given that, Nanoviricides claims their current cash on hand will sustain them until their first human trials. The company is highly speculative but certainly any signs of a revenue stream, progress towards human trials, or an announcement showing interest by a major pharmaceutical company should put the company on investors’ radar.
